Synchronous early‑stage breast cancer and axillary follicular lymphoma diagnosed by core needle biopsy: A case report

Eto, Ryotaro; Nakamura, Rikiya; Yamamoto, Nobuto; Miyaki, Toshiko; Hayama, Shoko; Sonoda, Itaru; Itami, Makiko; Tsujimura, Hideki; Hashimoto, Hideyuki; Otsuka, Masayuki

doi:10.3892/mco.2021.2436

Cited by 2 publications

(2 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 However, metachronous or synchronous presentation of breast cancer (BC) and follicular lymphoma (FL) is rare. [3][4][5] It is not clear whether these two neoplasms occur by mutually promoting mechanisms and the consensus is lacking on how to treat patients with co-existing BC and FL since different stages of each disease predict diverse prognosis and demand utterly different kinds of treatment. Treatment decisions should be made by a multidisciplinary team (MDT) after the individual prognoses of both malignancies have been scrupulously weighed, and a win-win situation has been negotiated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Successful Treatment of Concurrent Follicular Lymphoma and Triple-Negative Breast Cancer Using Rituximab Plus Nab-Paclitaxel and Cisplatin: A Case Report and Literature Review

Zhu,

Zhou,

et al. 2023

OTT

View full text Add to dashboard Cite

Background Co-occurrence of breast cancer and non-Hodgkin’s lymphoma is a rare condition with diagnostic and therapeutic challenges. The coexistence of follicular lymphoma (FL) and triple-negative breast cancer (TNBC) has not been described previously. Case Presentation A 46-year-old woman, already suffering a history of untreated, advanced-stage, high tumor burden FL, was admitted for a rapidly progressing right breast mass. Ultrasonography showed an 8.3 × 3.6 × 4.1 cm fungating mass in the right breast with enlarged lymph nodes (LNs) in bilateral axillae. PET-CT demonstrated increased 18 F- FDG activity in right breast mass, LNs on both sides of the diaphragm, enlarged spleen, and bone marrow. Biopsy of the right breast mass revealed TNBC. The patient underwent neoadjuvant therapy with R-CHOP and achieved partial response of breast tumor. However, TNBC progressed after three cycles of R-CHOP. According to the next-generation sequencing (NGS) assay on breast mass showing a homologous recombination repair (HRR) deficiency (HRD) score of 72, the neoadjuvant regimen was changed to rituximab plus nab-paclitaxel and cisplatin (R-TP) and resulted in significant tumor regression. The patient then underwent right mastectomy with an axillary LN dissection. After the surgery, she was regularly monitored and given adjuvant therapy with R-TP and radiotherapy. Conclusion The coexistence of FL and HRD-positive TNBC poses diagnostic and treatment challenges. Well-founded neoadjuvant strategy based on multidisciplinary team (MDT) discussion and NGS warranted a good outcome in this case.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Triple-negative breast cancer (TNBC), representing 10-15% of BCs 4 , is the most aggressive subtype with abysmal outcomes. Currently, treatment modalities for TNBC without distant metastasis include surgery, chemotherapy, and radiology.…”

Section: Introductionmentioning

confidence: 99%